Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

564 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Among authors: bianco r. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Rosa R, et al. Among authors: bianco r. Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19. Clin Cancer Res. 2013. PMID: 23166225
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F. Troiani T, et al. Among authors: bianco r. Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27. Clin Cancer Res. 2015. PMID: 26019172
Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. D'Amato V, et al. Among authors: bianco r. Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Cancer Treat Rev. 2015. PMID: 26276735 Review.
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Formisano L, et al. Among authors: bianco r. Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27. Clin Cancer Res. 2017. PMID: 28751448 Free PMC article.
Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Formisano L, et al. Among authors: bianco r. Clin Cancer Res. 2019 Feb 15;25(4):1433. doi: 10.1158/1078-0432.CCR-18-4268. Clin Cancer Res. 2019. PMID: 30770492 No abstract available.
Mechanisms of resistance to mTOR inhibitors.
Formisano L, Napolitano F, Rosa R, D'Amato V, Servetto A, Marciano R, De Placido P, Bianco C, Bianco R. Formisano L, et al. Among authors: bianco r, bianco c. Crit Rev Oncol Hematol. 2020 Mar;147:102886. doi: 10.1016/j.critrevonc.2020.102886. Epub 2020 Jan 29. Crit Rev Oncol Hematol. 2020. PMID: 32014673 Review.
564 results